Black Diamond submits IND for BDTX-1535 ahead of schedule; cash runway extended to 2024

Black Diamond Therapeutics, Inc.

IND submitted for BDTX-1535 (CNS-penetrant EGFR inhibitor) for GBM and NSCLC; Phase 1 expected Q1 2022 subject to FDA allowance.
Company to enroll additional patients in BDTX-189 safety expansion; Phase 2 start gated pending further data.
Ended 2021 with ~$210M cash, sufficient to fund operations into 2024.
Anticipates IND-enabling studies for CNS-penetrant BRAF program in 2022.
Preclinical data shows BDTX-1535 activity in intracranial tumor models; targets ~50% of GBM patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.